Bern-based LEM Surgical raises €23.6 million in series B round funding. The round was significantly oversubscribed, which is indicative of the strong confidence investors have in LEM Surgical’s unique strategy.
The significant increase in funding can be ascribed to the eager participation of fresh investors from Switzerland and the United States. The purpose of the capital infusion is to strategically advance LEM Surgical’s product development initiatives and position the company for FDA submission in the second half of 2024.
With this most recent round of funding, LEM Surgical is in a strong position to meet its goals and further establish its potential in the surgical robotics industry.
Yossi Bar, founder and CEO of LEM Surgical, said: “Our goal is to revolutionize the experience for surgeons, clinical teams, and hospitals engaged in robotic surgery. We deeply appreciate the trust and support of our new investors. It underscores the unwavering confidence our investors have in the future success of our groundbreaking technology.”
LEM Surgical is leading the way in developing the upcoming robotic surgery platforms that will shape the future. Its development efforts are primarily focused on improving upon the capabilities of current robotic platforms used in spine surgery.
About LEM Surgical
Prof. Dr. Stefan Weber, the CEO of CAScination AG; Marco Matulic, the CTO of CAScination AG; Simon Michel, the CEO of the Ypsomed Group; Prof. Dr. Andreas Raabe, the director of the department of neurosurgery at Inselspital Bern; and Yossi Bar, the former director of R&D at Mazor Robotics Ltd., founded the company in 2021.
The goal of LEM Surgical is to introduce robotic surgery platforms that will improve the healthcare industry. First, we will revolutionise robotic surgery by developing and bringing to market a novel, cutting-edge, and useful spine surgery robotic system.